Moleculin Biotech Inc. (NASDAQ: MBRX) announced the release of a new CEO Corner segment featuring Chief Executive Officer Walter Klemp discussing the company's MIRACLE study progress.

The segment focuses on the company's pivotal MIRACLE study evaluating Annamycin in combination with cytarabine for patients with relapsed or refractory acute myeloid leukemia. The adaptive Phase 3 trial was designed with input from the U.S. Food and Drug Administration and includes an initial cohort of 45 patients.

According to the company, enrollment and dosing across clinical sites are progressing as planned, with completion of treatment for the first 45 patients expected in the near term. After treatment of these patients is completed, the study will undergo an interim unblinding to evaluate safety and efficacy.

The study builds on results from the company's earlier MB-106 study, in which the drug combination demonstrated overall survival outcomes that exceeded historical benchmarks in this patient population, according to Moleculin.

Moleculin describes itself as a Phase 3 clinical stage pharmaceutical company developing therapeutic candidates for hard-to-treat tumors and viruses. The company's lead program, Annamycin, is an anthracycline designed to avoid multidrug resistance mechanisms and reduce cardiotoxicity associated with currently prescribed anthracyclines.

The CEO Corner platform is designed to provide investors and stakeholders with insight into the company's corporate developments, clinical progress and strategic initiatives, according to the press release.